Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBG453 with or without azacitidine in progressive acute myeloid leukemia within the AMLM26 INTERCEPT platform
ACTRN12621001265864Phase 2Active, not recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of sabatolimab in acute myeloid leukemia (AML) (2 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: MRD clearance rate. Started Aug 2022; status: active, not recruiting.
02
Drugs
sabatolimab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12621001265864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001265864.